Excellent link Aussienorm. You are absolutely right J8. I did not mean to be misleading, the data I got from Duke was of a general nature as they obviously would not comment on specific cases. So to correct my earlier post I have copied below part of the selection criteria taken from Aussienorm's link.
Eligibility
Ages Eligible for Study: 18 Years to 65 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No
Inclusion Criteria:
Subjects must a history of chronic HCV infection defined as documented HCV genotype 1 infection for at least 6 months. •Subjects must have: a.Documented failure to respond to prior treatment or relapse with a combination of peg-interferon (peg-IFN), ribavirin (RBV), and either boceprevir or telaprevir, OR a combination of peg-IFN and ribavirin or b.Subject is ineligible or unwilling to receive a combination of peg-IFN, RBV, and either boceprevir or telaprevir.
BLT Price at posting:
$1.80 Sentiment: None Disclosure: Held
